Dr Stock Pick HOT News & Alerts!
_________________________________________
FREE Daily Stock Alerts From DrStockPick.com
_________________________________________
Wednesday October 7, 2009
DrStockPick.com Stock Report!
RPRX, PWRM, WYN, CSRH, BX, CVAT, DELL, AQNM, IBM
RPRX, Repros Therapeutics Inc.
RPRX focuses on the development of oral small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Secondary hypogonadism is a deficiency state in which the male hormone testosterone goes below the normal range, even in aging men, due to inadequate stimulation of the testes by the pituitary.
The results from an exploratory, efficacy and safety study of RPRX’s oral investigational product, enclomiphene citrate (Androxal�), in men with secondary hypogonadism who were receiving testosterone replacement treatment shows that RPRX’s Androxal� increased both LH (luteinizing hormone) and FSH (follicle stimulating hormone) while men on Testim had significantly lower levels of these important fertility related hormones.
Dr. Jed Kaminetsky (Department of Urology, New York University Medical Center), the lead investigator noted, �Androxal may fill the need for a drug that is able to restore testicular function and at the same time provide the benefits that normalization of testosterone provides to hypogonadal men. If Androxal can be safely developed, it will represent an important new treatment option for men with secondary hypogonadism with a continued fertility interest.�
RPRX hopes to submit a request for a meeting to the FDA to determine whether the Agency deems these observations to be clinically relevant and whether a development program can be designed to confirm the findings of this exploratory study, and ultimately support a label for the treatment of secondary hypogonadism in men who wish to preserve their fertility.
PWRM, Power 3 Medical Products Inc, PWRM.OB
Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3�s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer�s disease (NuroPro-AD), and Parkinson�s disease (NuroPro-PD) in 2009 and for breast cancer in 2010, followed by filings with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer�s, and Parkinson�s diseases, and breast cancer.
PWRM Announced that its Chief Scientific Officer is Chair and Keynote Speaker of Session at the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 2009
Further international recognition of validity as the company�s President and CSO, Dr. Ira Goldknopf will deliver an invited Keynote address and chair a session on �Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),� at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is �New Leadership of Personalized Medicine.�
More about PWRM at www.power3medical.com
WYN, Wyndham Worldwide Corporation
WYN provides various hospitality products and services to individual consumers and business customers. The company?s Lodging segment franchises hotels in the upscale, middle, and economy segments of the lodging industry, as well as provides property management services to owners of these hotels.
Goldman Sachs’s Analyst Steven Kent raised his rating on WYN to “Buy” from “Neutral” and increased his share price target to $26 from $18.
CSRH, Consorteum Holdings Inc, CSRH.OB
CSRH announced a corporate update with respect to its business activities. Over the course of the past 60 days, several meetings and presentations have occurred between the Company�s management and various corporations, private and public, to further the development of the company�s Card Programs, Merchant Discount Rates and new Joint Venture business relationship. As a result of these meetings, we have identified several new key business opportunities that will lead to increased revenues in 2010-2011.
As previously announced, we have signed a joint venture agreement with Trans Screen Group. Through this newly established joint venture relationship, Trans Screen Group and Consorteum Holdings Inc. will expand into markets outside North America targeting new opportunities in India, Africa, Russia, Latin America, Thailand and China for payroll / benefits cards, loyalty programs, gift cards, payment transaction processing and several other value added services. The Trans Screen Group has established business relationships within these countries and will leverage Consorteum�s expertise to provide financial services to their existing partners.
Consorteum has also been in discussion with several companies within the payroll industry to develop new payroll card programs. Proposals have been presented and we will continue to develop these relationships to reach the deployment phase.
Furthermore, �My Golf Rewards� finalized its pilot program over the summer and has completed all testing and platform development. The next phase of engagement is adding 20 new golf courses to the program in early 2010. We are also planning to further expose the My Golf Rewards program to golf courses owners and end consumers through trade shows and industry publications.
We continue to explore adding industry professionals and experts who have experience in the areas of banking, credit card issuance, payment processing, rebates and payroll. In addition, the Company is currently looking to expand its Board of Directors and Board of Advisors with financial services industry experts and senior executive level professionals running successful and profitable organizations. We will be providing further press releases and corporate updates to our shareholders and the investment community within the next 30 days.
More about CSRH at www.consorteum.com
BX, The Blackstone Group
BX, together with its subsidiaries, provides alternative asset management and financial advisory services worldwide. The company operates in four segments: Corporate Private Equity, Real Estate, Marketable Alternative Asset Management, and Financial Advisory.
BX, plans to buy Anheuser-Busch InBev’s U.S. theme parks for up to $2.7 billion
CVAT, Cavitation Technologies Inc, CVAT.OB
CVAT has announced that it has filed PCT patent applications for new International Patent protections for its Nano Cavitation Technologies.
According to Igor Gorodnitsky, CTI�s President and Director of Research and Development, �CTI continues to identify new applications for our technology. All of the applications are in industries where there is a need to solve environmental problems, reduce operating costs and improve profitability. We have hundreds of international inquiries from companies that want our technology and as a result we needed to file International Patents to protect our Intellectual Property worldwide. These technologies have significant benefit and value for the vegetable oil refining, renewable fuels, petroleum, water desalination, wastewater treatment, food and beverage, chemical industries.�
As indicated by the patent attorney from the firm Kelly Lowry and Kelley, �Some of the CTI applications have been filed so as to protect the various highly innovative technologies developed by Cavitation Technologies, Inc. concerning industries needing Green technologies to reduce their carbon footprint, reduce the use of chemicals and costs.�
These PCT international CTI applications should be published by the end of August 2010. The Company looks forward to proceeding with the national phase entries in various countries in order to protect its technologies in countries.
�We are particularly proud of the fact that the technologies we are developing will have international impact,� indicated Roman Gordon, Cavitation Technologies, Inc. CEO. �As we continue to develop our intellectual property portfolio, we are also exploring relationships with potential strategic partners to enable worldwide transformation of a number of chemical, wastewater, renewable fuels and vegetable oil processes.�
CVAT More about CVAT at www.cavitationtechnologies.com
DELL, Dell Inc.
DELL, together with its subsidiaries, engages in the design, development, manufacture, marketing, sale, and support of computer systems and services worldwide
DELL will close a desktop computer manufacturing plant in Winston-Salem, N.C., by the end of January.
AQNM, Aquentium, Inc., AQNM.OB
Aquentium, Inc. (OTCBB: AQNM) a publicly traded company with a focus on �green technologies� is pleased to announce that the company�s non-chemical technology sanitizes fruits and vegetables naturally without the use of any chemicals.
The Aquentium non-chemical sanitation equipment is designed for improved food safety standards both domestically and internationally. Aquentium is currently offering exclusive representation opportunities for its complete line of non-chemical processing and sanitation equipment for fruits and vegetables in countries throughout the world as well in all fifty states in the USA
The goal at Aquentium is to help prevent contamination of fresh fruits and vegetables. The Aquentium non-chemical process can extend the shelf life of produce which means higher profits for food processors and less waste for the consumer.
The uniqueness of the Aquentium technology is that it is over 50% more effective than chemicals and over 3,000 times faster acting than chemicals. Ultimately, Aquentium believes that we have better technology to combat e-coli, salmonella, listeria and other bacteria or viruses than what most food processors are currently using.
With the Aquentium equipment, a processor does not have to stop processing to do plant sanitation. This increases plant production. Furthermore, food processors can expect an ROI in less than 12 months using the Aquentium equipment.
More about AQNM at www.aquentium.com
IBM, International Business Machines Corp.
IBM develops and manufactures information technology products and services worldwide.
Investment manager Franklin Resources Inc. is cutting short a services contract with IBM
Keep a close eye on RPRX, PWRM, WYN, CSRH, BX, CVAT, DELL, AQNM and IBM do your homework, and like always BE READY for the ACTION!
No comments:
Post a Comment